Has larotrectinib been included in my country's medical insurance system?

Larotinib, this innovative anti-cancer drug, has been successfully launched in China, but as of now, it has not been officially included in my country's medical insurance system. Therefore, for patients who need to use this drug, it may be difficult to purchase it directly in the hospital. In order to ensure smooth access to medicines, it is recommended that patients consult the pharmacy of their hospital in advance in order to keep abreast of the latest drug purchase information and procedures.

In the international market, both the original drug and generic drugs of larotrectinib are available. In terms of original drugs, patients can choose versions from Germany, the United States, Europe and Hong Kong, China, with prices ranging from RMB 10,000 to RMB 20,000. The price of generic drugs, such as the Lao version and the Bangladeshi version, is relatively low, generally only about two to three thousand yuan. Although the main ingredients of original drugs and generic drugs are similar, the prices will be different due to differences in production sources and manufacturing processes.

For the majority of patients, when choosing drugs, they need to comprehensively consider their own financial situation, medical insurance conditions, and personal medication preferences. Although larotrectinib is not yet included in medical insurance, patients can still choose a version of the drug that suits them in domestic and foreign markets based on their actual conditions.

In addition, patients should be cautious when purchasing drugs, and it is best to make decisions under the professional guidance of a doctor or pharmacist. At the same time, it is recommended that patients always pay attention to relevant medical insurance policy updates so that they can learn about changes in drug purchase channels and price information as soon as possible after larotrectinib is included in the medical insurance system.